The KEGG results revealed that oridonin could target to treat TNBC, encompassing PI3K/Akt signaling, proteoglycans in cancer, human cytomegalovirus infection, MAPK signaling, lipid metabolism, and atherosclerosis, among others. This evidence concerns the gene AKT1 and atherosclerosis.